Mirja Rotinen

发表

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis

Simon G. Coetzee, P. Nelson, S. Freedland, 2018, Nature Medicine.

Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis

Ian H. Guldner, V. te Boekhorst, Jessica L. Christenson, 2019, Clinical & Experimental Metastasis.

Estradiol induces type 8 17beta-hydroxysteroid dehydrogenase expression: crosstalk between estrogen receptor alpha and C/EBPbeta.

M. Alonso, I. Encío, Mirja Rotinen, 2009, The Journal of endocrinology.

Changes in Gene Expression Profiling of Apoptotic Genes in Neuroblastoma Cell Lines upon Retinoic Acid Treatment

J. Castresana, I. Encío, P. Lázcoz, 2013, PloS one.

Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer.

S. Freedland, Jayoung Kim, D. Di Vizio, 2021, American journal of clinical and experimental urology.

Transcriptional regulation of the human type 8 17β-hydroxysteroid dehydrogenase gene by C/EBPβ

M. Alonso, C. Miguel, I. Encío, 2007, The Journal of Steroid Biochemistry and Molecular Biology.

Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease.

M. Rubin, F. Demichelis, M. Klagsbrun, 2012, The American journal of pathology.

Type 10 17β-hydroxysteroid dehydrogenase expression is regulated by C/EBPβ in HepG2 cells

I. Encío, Mirja Rotinen, J. Villar, 2010, The Journal of Steroid Biochemistry and Molecular Biology.

“Defining the Independence of the Liver Circadian Clock” & “BMAL1-Driven Tissue Clocks Respond Independently to Light to Maintain Homeostasis”

Mirja Rotinen, 2020, Frontiers in Neuroscience.

Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage

I. Encío, Mirja Rotinen, J. Villar, 2012, Journal of Physiology and Biochemistry.

Transcriptional regulation of type 11 17β-hydroxysteroid dehydrogenase expression in prostate cancer cells

V. Notario, I. Encío, Mirja Rotinen, 2011, Molecular and Cellular Endocrinology.

27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6–JAK–STAT3 Signaling in Prostate Cancer Cells

J. Turkson, S. Freedland, J. Chi, 2020, Molecular Cancer Research.

Cutting down on lung cancer: Ecliptasaponin A is a novel therapeutic agent.

I. Encío, Mirja Rotinen, 2020, Annals of translational medicine.

Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential.

Hisashi Tanaka, H. Tseng, L. Chung, 2018, Cancer research.

Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis

Ian H. Guldner, V. te Boekhorst, Jessica L. Christenson, 2019, Clinical & Experimental Metastasis.

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer

I. Encío, Mirja Rotinen, Irene Zamora, 2023, International journal of molecular sciences.

ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis

Simon G. Coetzee, Dennis J. Hazelett, P. Nelson, 2018, Nature Medicine.

Actionable Driver Events in Small Cell Lung Cancer

I. Encío, Mirja Rotinen, Irene Zamora, 2023, International journal of molecular sciences.

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer

C. Morrissey, I. Garraway, E. Mostaghel, 2023, bioRxiv.

ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.

M. Pajares, Mirja Rotinen, Irene Zamora, 2024, Cellular oncology.

ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer

C. Morrissey, I. Garraway, E. Mostaghel, 2024, Nucleic acids research.

ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer

M. Freeman, S. You, Mirja Rotinen, 2019, Translational cancer research.